Physician profile
Paul C Wang
NPI 1508839481
$7,175.47
in general payments reported to CMS, 2019-2025
50 companies · $794 in 2025
The $794 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $913 · 2020: $1,166 · 2021: $1,449 · 2022: $1,668 · 2023: $646 · 2024: $539 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,978.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $818.41 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Lilly USA, LLC | $603.21 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Novo Nordisk INC | $530.62 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $519.92 | 2019-2025 | Jardiance, Tradjenta, Glyxambi |
| Abbvie INC. | $463.76 | 2021-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $373.50 | 2019-2024 | Trelegy Ellipta, Pediarix, Bexsero |
| Pfizer INC. | $371.70 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $356.48 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $282.86 | 2019-2023 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $252.55 | 2019-2025 | |
| Allergan, INC. | $245.04 | 2019-2020 | |
| Astellas Pharma US INC | $229.48 | 2019-2023 | Veozah |
| Sanofi-Aventis U.S. LLC | $181.36 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $172.08 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $161.87 | 2022-2025 | Caplyta |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.